An overview of PROTACs: a promising drug discovery paradigm

Proteolysis targeting chimeras (PROTACs) technology has emerged as a novel therapeutic paradigm in recent years. PROTACs are heterobifunctional molecules that degrade target proteins by hijacking the ubiquitin-proteasome system. Currently, about 20-25% of all protein targets are being studied, and most works focus on their enzymatic functions. Unlike small molecules, PROTACs inhibit the whole biological function of the target protein by binding to the target protein and inducing subsequent proteasomal degradation. PROTACs compensate for limitations that transcription factors, nuclear proteins, and other scaffolding proteins are difficult to handle with traditional small-molecule inhibitors. Currently, PROTACs…

• NN
  National Natural Science Foundation of China

  Awards: 22007070, 22277086
• DO
  Department of Science and Technology of Sichuan Province

  Awards: 2022ZDZX0028, 2022NSFSC1409
• SU
  Sichuan University

  Awards: 2021HXBH006, ZYJC21075
• SP
  Sichuan Province Science and Technology Support Program

  Awards: 2022NSFSC1409, 2022ZDZX0028
• WC
  West China Hospital, Sichuan University

  Awards: ZYJC21075, 2021HXBH006, 1.3.5